Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
ETX.L Share News (ETX)
ETX Share
Price
ETX Share
News
ETX Share
Chat
ETX Share
Trades
ETX
Live RNS
ETX Share
Charts
ETX Broker
Ratings
ETX Directors
Deals
ETX Financial
Diary
ETX
Fundamentals
ETX Short
Positions
ETX
Media
ETX Company
Research
ETX Company
Timeline
- There is currently no data for ETX
e-Therapeutics Development Director Steve Self To Step Down
LONDON (Alliance News) - e-Therapeutics PLC on Wednesday said Development Director Steve Self will leave at the end of September, following a strategic refocus by the drug discovery company.
"Steve joined e-Therapeutics in December 2010 following a distinguished career at The Wellcome Foundation, Boots Healthcare and as R&D Director of Merck's Generic Global business. We thank him for his significant contribution to our activities and wish him continuing success in his new endeavours," said Executive Chairman Iain Ross in a statement.
Shares in e-Therapeutics were untraded Wednesday afternoon. They last closed at 10.56 pence.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Latest ETX News
- e-Therapeutics proposes £29m fundraising, delisting from AIM
10 Apr 2024 - e-Therapeutics says company faces lack of interest as UK listing
10 Apr 2024 - IN BRIEF: e-Therapeutics shares rise on strong financial year
16 Jan 2024 - IN BRIEF: e-Therapeutics shares to cease trading on OTCQX
27 Dec 2023 - EARNINGS AND TRADING: Kanabo inks CBD deal, Taseko boosts production
2 Nov 2023 - E-Therapeutics enters collaboration with Arcturis Data
2 Nov 2023 - EARNINGS: Riverstone Credit stays stable, Bloomsbury hails record half
26 Oct 2023 - UK earnings, trading statements calendar - next 7 days
19 Oct 2023
Related News
e-Therapeutics proposes £29m fundraising, delisting from AIM
(Sharecast News) - RNAi medicines data and development specialist e-Therapeutics proposed a fundraise and its delisting from AIM on Wednesday.
e-Therapeutics says company faces lack of interest as UK listing
(Alliance News) - e-Therapeutics PLC on Wednesday announced its intention to cancel its admission to AIM and instead explore the option of listing on ...
IN BRIEF: e-Therapeutics shares rise on strong financial year
e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Says 2023 was
ETX.L News
e-Therapeutics proposes £29m fundraising, delisting from AIM
(Sharecast News) - RNAi medicines data and development specialist e-Therapeutics proposed a fundraise and its delisting from AIM on Wednesday.
e-Therapeutics says company faces lack of interest as UK listing
(Alliance News) - e-Therapeutics PLC on Wednesday announced its intention to cancel its admission to AIM and instead explore the option of listing on ...
IN BRIEF: e-Therapeutics shares rise on strong financial year
e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Says 2023 was
IN BRIEF: e-Therapeutics shares to cease trading on OTCQX
e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Says that its shares will cease to trade on the OTCQX Best Market i...
EARNINGS AND TRADING: Kanabo inks CBD deal, Taseko boosts production
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately report...
E-Therapeutics enters collaboration with Arcturis Data
(Sharecast News) - E-Therapeutics announced a strategic collaboration with Arcturis Data on Thursday - a prominent UK data company known for its high-...
EARNINGS: Riverstone Credit stays stable, Bloomsbury hails record half
(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Wednesday and Thursday, and not separately rep...
Follow the stocks
